Advertisement

Impedance Measurement in Induced Pluripotent Stem Cell-Derived Cardiomyocytes

  • Emma-Jane PoultonEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1641)

Abstract

Impedance-based measurement is a useful tool for assessing the contractility of plated cardiomyocytes in the context of early preclinical cardiosafety assessment. Induced pluripotent stem cell-derived cardiomyocytes (iPSCs) can be used for this purpose as these cells display similar electrochemical properties to primary cardiomyocytes and beat reliably and in synchronicity in culture. Here we describe a method for measuring the contractility of iPSCs using the xCELLigence RTCA impedance measurement system.

Key words

iPSC cardiomyocytes iCells cardiomyocytes Contractility measurement Impedance Cardiosafety 

References

  1. 1.
    Shah RR (2005) Drugs, QT interval prolongation and ICH E14: the need to get it right. Drug Saf 28(2):115–125CrossRefPubMedGoogle Scholar
  2. 2.
    Stevens JL, Baker TK (2009) The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 14(3–4):162–167CrossRefPubMedGoogle Scholar
  3. 3.
    Brown AM (2005) HERG block, QT liability and sudden cardiac death. Novartis Found Symp 266:118–131; discussion 131–135, 155–158Google Scholar
  4. 4.
    Fermini B, Fossa AA (2003) The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2(6):439–447CrossRefPubMedGoogle Scholar
  5. 5.
    Valentin JP, Bialecki R, Ewart L, Hammond T, Leishmann D, Lindgren S, Martinez V, Pollard C, Redfern W, Wallis R (2009) A framework to assess the translation of safety pharmacology data to humans. J Pharmacol Toxicol Methods 60(2):152–158CrossRefPubMedGoogle Scholar
  6. 6.
    Denning C, Anderson D (2008) Cardiomyocytes from human embryonic stem cells as predictors of cardiotoxicity. Drug Discov Today: Ther Strateg 5(4):223–232Google Scholar
  7. 7.
    Ma J, Guo L, Fiene SJ, Anson BD, Thomson JA, Kamp TJ, Kolaja KL, Swanson BJ, January CT (2011) High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol 301(5):H2006–H2017CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Nguemo F, Saric T, Pfannkuche K, Watzele M, Reppel M, Hescheler J (2012) In vitro model for assessing arrhythmogenic properties of drugs based on high-resolution impedance measurements. Cell Physiol Biochem 29(5–6):819–832CrossRefPubMedGoogle Scholar
  9. 9.
    Harris K, Aylott M, Cui Y, Louttit JB, McMahon NC, Sridhar A (2013) Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol Sci 134(2):412–426CrossRefPubMedGoogle Scholar
  10. 10.
    Huebsch N, Loskill P, Mandegar MA, Marks NC, Sheehan AS, Ma Z, Mathur A, Nguyen TN, Yoo JC, Judge LM, Spencer CI, Chukka AC, Russell CR, So PL, Conklin BR, Healy KE (2014) Automated video-based analysis of contractility and calcium flux in human-induced pluripotent stem cell-derived cardiomyocytes cultured over different spatial scales. Tissue Eng Part C Methods 21(5):467–479CrossRefGoogle Scholar
  11. 11.
    Peters MF, Lamore SD, Guo L, Scott CW, Kolaja KL (2014) Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line. Cardiovasc Toxicol 15(2):127–139CrossRefGoogle Scholar
  12. 12.
    Xi B, Wang T, Li N, Ouyang W, Zhang W, Wu J, Xu X, Wang X, Abassi YA (2011) Functional cardiotoxicity profiling and screening using the xCELLigence RTCA cardio system. J Assoc Lab Autom 16(6):415–421CrossRefGoogle Scholar
  13. 13.
    Guo L, Abrams RMC, Babiarz JE, Cohen JD, Kameoka S, Sanders MJ, Chiao E, Kolaja KL (2011) Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci 123(1):281–289CrossRefPubMedGoogle Scholar
  14. 14.
    Abassi YA, Xi B, Li N, Ouyang W, Seiler A, Watzele M, Kettenhofen R, Bohlen H, Ehlich A, Kolossov E, Wang X, Xu X (2012) Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. Br J Pharmacol 165(5):1424–1441CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  1. 1.Preclinical SafetySanofiFraminghamUSA

Personalised recommendations